# Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients

> **NCT06228092** · PHASE4 · COMPLETED · sponsor: **Matias Vested** · enrollment: 40 (actual)

## Conditions studied

- Neuromuscular Blockade, Residual

## Interventions

- **DRUG:** neostigmine/glycopyrrolate
- **DRUG:** Sugammadex

## Key facts

- **NCT ID:** NCT06228092
- **Lead sponsor:** Matias Vested
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-04
- **Primary completion:** 2025-05-04
- **Final completion:** 2025-05-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06228092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06228092, "Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06228092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*